Literature DB >> 25322333

Chitosan aerosol inhalation alleviates lipopolysaccharide- induced pulmonary fibrosis in rats.

Lu-Lu Zhou1, Xing-Ying He, Feng-Ying Xu, Bo-Xiang Du, Zui Zou, Xue-Yin Shi.   

Abstract

PURPOSE: Pulmonary fibrosis (PF) is an insidiously progressive scarring disorder of the alveoli and is associated with high mortality. Currently, therapies available are associated with restricted efficacy and side effects. This study aimed to investigate the effect of chitosan aerosol inhalation on lipopolysaccharide (LPS)-induced pulmonary remodeling and fibrosis in rats.
METHODS: A rat model of PF was established by intratracheal injection of LPS (5 mg/kg). Chitosan was nebulized to rats from day 4 to 28 after LPS injection. We analyzed the effect of chitosan on LPS-induced pulmonary remodeling and fibrosis by hematoxylin-eosin staining (HE), Masson staining, and the determination of the hydroxyproline content. The expression intensities of matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were analyzed by western blots.
RESULTS: Histological assessments showed that chitosan aerosol inhalation attenuated the fibrotic changes in LPS-induced PF in rats. Compared with the LPS group, the fibrosis parameters were significantly improved in the LPS + chitosan group (LCh group), although not as good as those of the control group. The expressions of MMP-3 and TIMP-1 in the LCh group were markedly less than that of the LPS group on the 28th day.
CONCLUSIONS: Our findings show that chitosan aerosol inhalation inhibits the expression of MMP-3 and TIMP-1, and ameliorates LPS-induced pulmonary remodeling and fibrosis in rats.

Entities:  

Keywords:  chitosan; lipopolysaccharide; matrix metallopmteinase-3; pulmonary fibrosis; tissue inhibitor of metalloproteinase-1

Mesh:

Substances:

Year:  2014        PMID: 25322333     DOI: 10.3109/01902148.2014.948231

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  3 in total

1.  Oral Administration of Chitosan Attenuates Bleomycin-induced Pulmonary Fibrosis in Rats.

Authors:  You-Seok Kim; Qiang Li; Hwa-Young Youn; Dae Young Kim
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

2.  Combination therapy of chitosan, gynostemma, and motherwort alleviates the progression of experimental rat chronic renal failure by inhibiting STAT1 activation.

Authors:  Wenxia Bai; Shudong Wang; Shanshan An; Mengjie Guo; Guangming Gong; Wenya Liu; Shaoxin Ma; Xin Li; Jihua Fu; Wenbing Yao
Journal:  Oncotarget       Date:  2018-01-10

Review 3.  Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis.

Authors:  Josep Mercader-Barceló; Joan Truyols-Vives; Carlos Río; Nora López-Safont; Ernest Sala-Llinàs; Alice Chaplin
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.